Brain Tumor Pathology

, Volume 34, Issue 1, pp 20–27 | Cite as

ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations

  • Takahiro Ogishima
  • Kaoru Tamura
  • Daisuke Kobayashi
  • Motoki Inaji
  • Shihori Hayashi
  • Reina Tamura
  • Tadashi Nariai
  • Kenji Ishii
  • Taketoshi Maehara
Original Article


Recent studies on gliomas have shown frequent alterations in the alpha-thalassemia/mental retardation syndrome X-linked gene (ATRX). This study was designed to determine whether ATRX status correlates with uptake of 11C-methionine in WHO grades II and III gliomas. Sixty-two patients underwent 11C-methionine positron emission tomography scans prior to histological diagnosis. The tumor-to-normal ratio (T/N) of 11C-methionine uptake was calculated by dividing the maximum standardized uptake value (SUV) for the tumor by the mean SUV of the normal brain. After surgery, tumor samples were subjected to immunohistochemistry for ATRX and IDH1-R132H followed by IDH1/2 sequencing. Twenty-seven of the sixty-two patients were found to have the IDH mutation. Nine of the twenty-seven gliomas harboring IDH mutations exhibited loss of nuclear ATRX expression, which is accompanied with an astrocytic tumor lineage and a poor prognosis. The mean T/N ratio in tumors with loss of nuclear ATRX expression was 2.20 ± 0.53, i.e., significantly lower than that of tumors with ATRX retention (3.28 ± 1.32, p = 0.0171, U test). Our study showed ATRX status to correlate with the T/N ratio and the outcomes of WHO grade II and III glioma patients with the IDH1 mutation. Our data provide new information on the biology and imaging characteristics of gliomas.


Glioma 11 C-methionine Positron emission tomography ATRX IDH 



We thank Dr. Hiroaki Wakimoto (Harvard University, Boston) for invaluable advice. This work was supported by JSPS KAKENHI Grant Number 15K19954 (K. Tamura). Portions of this study were presented in abstract form at the 34th Annual Meeting of the Japan Society of Brain Tumor Pathology, Tokyo, Japan, May 27, 2016.

Compliance with ethical standards

Conflict of interest

The authors have no conflicts of interest to declare.

This study was approved by the Ethics Committee of the Tokyo Medical and Dental University. Informed consent was obtained from the patients and/or their guardians.

Supplementary material

10014_2017_280_MOESM1_ESM.tif (1.5 mb)
Supplementary material 1 (TIF 1521 KB)
10014_2017_280_MOESM2_ESM.tif (1.5 mb)
Supplementary material 2 (TIF 1521 KB)
10014_2017_280_MOESM3_ESM.docx (45 kb)
Supplementary material 3 (DOCX 45 KB)


  1. 1.
    Cancer Genome Atlas Research N, Brat DJ, Verhaak RG et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498CrossRefGoogle Scholar
  2. 2.
    Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820CrossRefPubMedGoogle Scholar
  3. 3.
    Suzuki H, Aoki K, Chiba K et al (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47:458–468CrossRefPubMedGoogle Scholar
  4. 4.
    Liu XY, Gerges N, Korshunov A et al (2012) Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 124:615–625CrossRefPubMedGoogle Scholar
  5. 5.
    Jiao Y, Killela PJ, Reitman ZJ et al (2012) Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 3:709–722CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Saito T, Maruyama T, Muragaki Y et al (2013) 11 C-methionine uptake correlates with combined 1p and 19q loss of heterozygosity in oligodendroglial tumors. AJNR Am J Neuroradiol 34:85–91CrossRefPubMedGoogle Scholar
  7. 7.
    Iwadate Y, Shinozaki N, Matsutani T et al (2016) Molecular imaging of 1p/19q deletion in oligodendroglial tumours with 11 C-methionine positron emission tomography. J Neurol Neurosurg Psychiatry 87:1016–1021CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Hartmann C, Meyer J, Balss J et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469–474CrossRefPubMedGoogle Scholar
  9. 9.
    Wiestler B, Capper D, Holland-Letz T et al (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443–451CrossRefPubMedGoogle Scholar
  10. 10.
    Reuss DE, Sahm F, Schrimpf D et al (2015) ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129:133–146CrossRefPubMedGoogle Scholar
  11. 11.
    Nojiri T, Nariai T, Aoyagi M et al (2009) Contributions of biological tumor parameters to the incorporation rate of L: -[methyl-(11)C] methionine into astrocytomas and oligodendrogliomas. J Neurooncol 93:233–241CrossRefPubMedGoogle Scholar
  12. 12.
    Nariai T, Tanaka Y, Wakimoto H et al (2005) Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 103:498–507CrossRefPubMedGoogle Scholar
  13. 13.
    Shinozaki N, Uchino Y, Yoshikawa K et al (2011) Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11 C-methionine positron emission tomography. J Neurosurg 114:1640–1647CrossRefPubMedGoogle Scholar
  14. 14.
    Louis DN, Ohgaki H, Wiestler OD et al (2007) World Health Organization histological classi cation of tumours of the central nervous system. International Agency for Research on Cancer, LyonGoogle Scholar
  15. 15.
    Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458CrossRefPubMedGoogle Scholar
  16. 16.
    Ishiwata K, Kubota K, Murakami M et al (1993) Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? J Nucl Med 34:1936–1943PubMedGoogle Scholar
  17. 17.
    Langen KJ, Muhlensiepen H, Holschbach M et al (2000) Transport mechanisms of 3-[123I]iodo-alpha-methyl-l-tyrosine in a human glioma cell line: comparison with [3H]methyl]-l-methionine. J Nucl Med 41:1250–1255PubMedGoogle Scholar
  18. 18.
    Bergstrom M, Lundqvist H, Ericson K et al (1987) Comparison of the accumulation kinetics of l-(methyl-11C)-methionine and d-(methyl-11C)-methionine in brain tumors studied with positron emission tomography. Acta Radiol 28:225–229PubMedGoogle Scholar
  19. 19.
    Wienhard K, Herholz K, Coenen HH et al (1991) Increased amino acid transport into brain tumors measured by PET of L-(2-18F)fluorotyrosine. J Nucl Med 32:1338–1346PubMedGoogle Scholar
  20. 20.
    Cha S, Tihan T, Crawford F et al (2005) Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 26:266–273PubMedGoogle Scholar
  21. 21.
    Lee JC, Jeng YM, Liau JY et al (2015) Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas. Mod Pathol 28:1064–1073CrossRefPubMedGoogle Scholar
  22. 22.
    Marinoni I, Kurrer AS, Vassella E et al (2014) Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology 146(453–460):e455Google Scholar
  23. 23.
    Kannan K, Inagaki A, Silber J et al (2012) Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 3:1194–1203CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Ikemura M, Shibahara J, Mukasa A et al (2016) Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas. Histopathology 69:260–267CrossRefPubMedGoogle Scholar

Copyright information

© The Japan Society of Brain Tumor Pathology 2017

Authors and Affiliations

  • Takahiro Ogishima
    • 1
  • Kaoru Tamura
    • 1
  • Daisuke Kobayashi
    • 2
  • Motoki Inaji
    • 1
    • 3
  • Shihori Hayashi
    • 1
    • 3
  • Reina Tamura
    • 2
  • Tadashi Nariai
    • 1
    • 3
  • Kenji Ishii
    • 3
  • Taketoshi Maehara
    • 1
  1. 1.Department of NeurosurgeryTokyo Medical and Dental UniversityTokyoJapan
  2. 2.Department of PathologyTokyo Medical and Dental UniversityTokyoJapan
  3. 3.Research Team for NeuroimagingTokyo Metropolitan Institute of GerontologyTokyoJapan

Personalised recommendations